{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,10,5]],"date-time":"2025-10-05T12:23:39Z","timestamp":1759667019936},"reference-count":54,"publisher":"Elsevier BV","issue":"3","license":[{"start":{"date-parts":[[2015,8,1]],"date-time":"2015-08-01T00:00:00Z","timestamp":1438387200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"content-domain":{"domain":["clinicalkey.es","elsevier.es","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Medicina Cl\u00ednica"],"published-print":{"date-parts":[[2015,8]]},"DOI":"10.1016\/j.medcli.2014.07.018","type":"journal-article","created":{"date-parts":[[2014,9,5]],"date-time":"2014-09-05T08:13:22Z","timestamp":1409904802000},"page":"124-130","update-policy":"http:\/\/dx.doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":5,"title":["Avances en el tratamiento anticoagulante de la fibrilaci\u00f3n auricular"],"prefix":"10.1016","volume":"145","author":[{"given":"Miguel","family":"Hern\u00e1ndez Olmedo","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Carmen","family":"Su\u00e1rez Fern\u00e1ndez","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.medcli.2014.07.018_bib0005","doi-asserted-by":"crossref","first-page":"943","DOI":"10.1016\/S0300-8932(02)76733-X","article-title":"La fibrilaci\u00f3n auricular permanente en las enfermedades cardiovasculares en Espa\u00f1a. Estudio CARDIOTENS 1999","volume":"55","author":"Garc\u00eda-Acu\u00f1a","year":"2002","journal-title":"Rev Esp Cardiol"},{"key":"10.1016\/j.medcli.2014.07.018_bib0010","doi-asserted-by":"crossref","first-page":"2370","DOI":"10.1001\/jama.285.18.2370","article-title":"Prevalence of diagnosed atrial fibrillation in adults: National implications for rhythm management and stroke prevention: The Anticoagulation and risk factors in atrial fibrillation (ATRIA) Study","volume":"285","author":"Go","year":"2001","journal-title":"JAMA"},{"key":"10.1016\/j.medcli.2014.07.018_bib0015","doi-asserted-by":"crossref","first-page":"616","DOI":"10.1157\/13107118","article-title":"Prevalence of atrial fibrillation in the Spanish population aged 60 years or more. The PREV-ICTUS study","volume":"60","author":"Cea-Calvo","year":"2007","journal-title":"Rev Esp Cardiol"},{"key":"10.1016\/j.medcli.2014.07.018_bib0020","doi-asserted-by":"crossref","first-page":"55","DOI":"10.1002\/clc.20138","article-title":"Update on atrial fibrillation: Part I","volume":"31","author":"Savalieva","year":"2008","journal-title":"Clin Cardiol"},{"key":"10.1016\/j.medcli.2014.07.018_bib0025","doi-asserted-by":"crossref","first-page":"983","DOI":"10.1161\/01.STR.22.8.983","article-title":"Atrial fibrillation as an independent risk factor for stroke: The Framingham Study","volume":"22","author":"Wolf","year":"1991","journal-title":"Stroke"},{"key":"10.1016\/j.medcli.2014.07.018_bib0030","first-page":"e15","article-title":"Atrial fibrillation and stroke: Epidemiology","volume":"127","author":"Reiffel","year":"2014","journal-title":"Am J Med"},{"key":"10.1016\/j.medcli.2014.07.018_bib0035","doi-asserted-by":"crossref","first-page":"884","DOI":"10.1111\/ene.12400","article-title":"Paroxysmal atrial fibrillation occurs often in cryptogenic ischaemic stroke. Final results from the SURPRISE study","volume":"21","author":"Christensen","year":"2014","journal-title":"Eur J Neurol"},{"key":"10.1016\/j.medcli.2014.07.018_bib0040","doi-asserted-by":"crossref","first-page":"392","DOI":"10.1161\/01.STR.32.2.392","article-title":"Characteristics, outcome, and care of stroke associated with atrial fibrillation in Europe: Data from a multicenter multinational hospital-based registry (The European Community Stroke Project)","volume":"32","author":"Lamassa","year":"2001","journal-title":"Stroke"},{"key":"10.1016\/j.medcli.2014.07.018_bib0045","doi-asserted-by":"crossref","first-page":"1375","DOI":"10.1093\/europace\/eur194","article-title":"The cost of illness of atrial fibrillation: A systematic review of the recent literature","volume":"13","author":"Wolowacz","year":"2011","journal-title":"Europace"},{"key":"10.1016\/j.medcli.2014.07.018_bib0050","doi-asserted-by":"crossref","first-page":"527","DOI":"10.1161\/01.CIR.84.2.527","article-title":"Stroke Prevention in Atrial Fibrillafion Study. Final results","volume":"84","year":"1991","journal-title":"Circulation"},{"key":"10.1016\/j.medcli.2014.07.018_bib0055","doi-asserted-by":"crossref","first-page":"1406","DOI":"10.1056\/NEJM199211123272002","article-title":"Warfarin in the prevention of stroke associated with nonrheumatic atrial fibrillation. Veterans Affairs Stroke Prevention in Nonrheumatic Atrial Fibrillation Investigators","volume":"327","author":"Ezekowitz","year":"1992","journal-title":"N Eng J Med"},{"key":"10.1016\/j.medcli.2014.07.018_bib0060","doi-asserted-by":"crossref","first-page":"857","DOI":"10.7326\/0003-4819-146-12-200706190-00007","article-title":"Meta-analysis: Antithrombotic therapy to prevent stroke in patients who have nonvalvular atrial fibrillation","volume":"146","author":"Hart","year":"2007","journal-title":"Ann Intern Med"},{"key":"10.1016\/j.medcli.2014.07.018_bib0065","doi-asserted-by":"crossref","first-page":"2864","DOI":"10.1001\/jama.285.22.2864","article-title":"Validation of clinical classification schemes for predicting stroke: Results from the National Registry of Atrial Fibrillation","volume":"285","author":"Gage","year":"2001","journal-title":"JAMA"},{"issue":"2 Suppl","key":"10.1016\/j.medcli.2014.07.018_bib0070","doi-asserted-by":"crossref","first-page":"e531S","DOI":"10.1378\/chest.11-2304","article-title":"Antithrombotic therapy for atrial fibrillation: Antithrombotic Therapy and Prevention of Thrombosis, 9th ed.: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines","volume":"141","author":"You","year":"2012","journal-title":"Chest"},{"key":"10.1016\/j.medcli.2014.07.018_bib0075","doi-asserted-by":"crossref","first-page":"263","DOI":"10.1378\/chest.09-1584","article-title":"Refining clinical risk stratification for predicting stroke and thromboembolism in atrial fibrillation using a novel risk factor-based approach: The euro heart survey on atrial fibrillation","volume":"137","author":"Lip","year":"2010","journal-title":"Chest"},{"key":"10.1016\/j.medcli.2014.07.018_bib0080","doi-asserted-by":"crossref","first-page":"2719","DOI":"10.1093\/eurheartj\/ehs253","article-title":"2012 focused update of the ESC Guidelines for the management of atrial fibrillation: An update of the 2010 ESC Guidelines for the management of atrial fibrillation. Developed with the special contribution of the European Heart Rhythm Association","volume":"33","author":"Camm","year":"2012","journal-title":"Eur Heart J"},{"key":"10.1016\/j.medcli.2014.07.018_bib0085","doi-asserted-by":"crossref","first-page":"649","DOI":"10.1016\/j.recesp.2011.03.014","article-title":"Impacto de los nuevos criterios para el tratamiento anticoagulante de la fibrilaci\u00f3n auricular","volume":"64","author":"Rodr\u00edguez-Ma\u00f1ero","year":"2011","journal-title":"Rev Esp Cardiol"},{"key":"10.1016\/j.medcli.2014.07.018_bib0090","doi-asserted-by":"crossref","first-page":"d124","DOI":"10.1136\/bmj.d124","article-title":"Validation of risk stratification schemes for predicting stroke and thromboembolism in patients with atrial fibrillation: Nationwide cohort study","volume":"342","author":"Olesen","year":"2011","journal-title":"BMJ"},{"key":"10.1016\/j.medcli.2014.07.018_bib0095","doi-asserted-by":"crossref","first-page":"1093","DOI":"10.1378\/chest.10-0134","article-title":"A novel user-friendly score (HAS-BLED) to assess 1-year risk of major bleeding in patients with atrial fibrillation: The Euro Heart Survey","volume":"138","author":"Pisters","year":"2010","journal-title":"Chest"},{"key":"10.1016\/j.medcli.2014.07.018_bib0100","doi-asserted-by":"crossref","first-page":"911","DOI":"10.1378\/chest.10-2436","article-title":"Prognosis and guideline-adherent antithrombotic treatment in patients with atrial fibrillation and atrial flutter. Implications of undertreatment and overtreatment in real-life clinical practice; the Loire Valley Atrial Fibrillation Project","volume":"140","author":"Gorin","year":"2011","journal-title":"Chest"},{"key":"10.1016\/j.medcli.2014.07.018_bib0105","doi-asserted-by":"crossref","first-page":"84","DOI":"10.1161\/CIRCOUTCOMES.108.796185","article-title":"Anticoagulation control and prediction of adverse events in patients with atrial fibrillation: A systematic review","volume":"1","author":"Wan","year":"2008","journal-title":"Circ Cardiovasc Qual Outcomes"},{"key":"10.1016\/j.medcli.2014.07.018_bib0110","doi-asserted-by":"crossref","first-page":"e63479","DOI":"10.1371\/journal.pone.0063479","article-title":"Risk profiles and antithrombotic treatment of patients newly diagnosed with atrial fibrillation at risk of stroke: Perspectives from the international, observational, prospective GARFIELD registry","volume":"8","author":"Kakkar","year":"2013","journal-title":"PLoS One"},{"key":"10.1016\/j.medcli.2014.07.018_bib0115","doi-asserted-by":"crossref","first-page":"1","DOI":"10.2165\/0003088-200948010-00001","article-title":"Comparative pharmacodynamics and pharmacokinetics of oral direct thrombin and factor Xa inhibitors in development","volume":"48","author":"Eriksson","year":"2009","journal-title":"Clin Pharmacokinet"},{"key":"10.1016\/j.medcli.2014.07.018_bib0120","doi-asserted-by":"crossref","first-page":"3554","DOI":"10.1182\/blood-2012-11-468207","article-title":"A specific antidote for dabigatran: Functional and structural characterization","volume":"121","author":"Schiele","year":"2013","journal-title":"Blood"},{"key":"10.1016\/j.medcli.2014.07.018_bib0125","doi-asserted-by":"crossref","first-page":"1139","DOI":"10.1056\/NEJMoa0905561","article-title":"Dabigatran versus warfarin in patients with atrial fibrillation","volume":"361","author":"Connolly","year":"2009","journal-title":"N Engl J Med"},{"key":"10.1016\/j.medcli.2014.07.018_bib0130","doi-asserted-by":"crossref","first-page":"883","DOI":"10.1056\/NEJMoa1009638","article-title":"Rivaroxaban versus warfarin in nonvalvular atrial fibrillation","volume":"365","author":"Patel","year":"2011","journal-title":"N Engl J Med"},{"key":"10.1016\/j.medcli.2014.07.018_bib0135","doi-asserted-by":"crossref","first-page":"981","DOI":"10.1056\/NEJMoa1107039","article-title":"Apixaban versus warfarin in patients with atrial fibrillation","volume":"365","author":"Granger","year":"2011","journal-title":"N Engl J Med"},{"key":"10.1016\/j.medcli.2014.07.018_bib0140","doi-asserted-by":"crossref","first-page":"2093","DOI":"10.1056\/NEJMoa1310907","article-title":"Edoxaban versus warfarin in patients with atrial fibrillation","volume":"369","author":"Giugliano","year":"2013","journal-title":"N Engl J Med"},{"key":"10.1016\/j.medcli.2014.07.018_bib0145","doi-asserted-by":"crossref","first-page":"955","DOI":"10.1016\/S0140-6736(13)62343-0","article-title":"Comparison of the efficacy and safety of new oral anticoagulants with warfarin in patients with atrial fibrillation: A meta-analysis of randomised trials","volume":"383","author":"Ruff","year":"2014","journal-title":"Lancet"},{"key":"10.1016\/j.medcli.2014.07.018_bib0150","doi-asserted-by":"crossref","first-page":"2363","DOI":"10.1161\/CIRCULATIONAHA.110.004747","article-title":"Risk of bleeding with 2 doses of dabigatran compared with warfarin in older and younger patients with atrial fibrillation: An analysis of the randomized evaluation of long-term anticoagulant therapy (RE-LY) trial","volume":"123","author":"Eikelboom","year":"2011","journal-title":"Circulation"},{"key":"10.1016\/j.medcli.2014.07.018_bib0155","doi-asserted-by":"crossref","first-page":"1349","DOI":"10.1253\/circj.CJ-13-1324","article-title":"Rivaroxaban vs. warfarin in Japanese patients with non-valvular atrial fibrillation in relation to age","volume":"78","author":"Hori","year":"2014","journal-title":"Circ J"},{"key":"10.1016\/j.medcli.2014.07.018_bib0160","doi-asserted-by":"crossref","first-page":"1864","DOI":"10.1093\/eurheartj\/ehu046","article-title":"Efficacy and safety of apixaban compared with warfarin according to age for stroke prevention in atrial fibrillation: Observations from the ARISTOTLE trial","volume":"35","author":"Halvorsen","year":"2014","journal-title":"Eur Heart J"},{"key":"10.1016\/j.medcli.2014.07.018_bib0165","doi-asserted-by":"crossref","first-page":"961","DOI":"10.1161\/CIRCULATIONAHA.113.003628","article-title":"Efficacy and safety of dabigatran compared with warfarin in relation to baseline renal function in patients with atrial fibrillation: a RE-LY (Randomized Evaluation of Long-term Anticoagulation Therapy) trial analysis","volume":"129","author":"Hijazi","year":"2014","journal-title":"Circulation"},{"key":"10.1016\/j.medcli.2014.07.018_bib0170","doi-asserted-by":"crossref","first-page":"632","DOI":"10.1253\/circj.CJ-12-0899","article-title":"Safety and efficacy of adjusted dose of rivaroxaban in Japanese patients with non-valvular atrial fibrillation: Subanalysis of J-ROCKET AF for patients with moderate renal impairment","volume":"77","author":"Hori","year":"2013","journal-title":"Circ J"},{"key":"10.1016\/j.medcli.2014.07.018_bib0175","doi-asserted-by":"crossref","first-page":"2821","DOI":"10.1093\/eurheartj\/ehs274","article-title":"Efficacy of apixaban when compared with warfarin in relation to renal function in patients with atrial fibrillation: Insights from the ARISTOTLE trial","volume":"33","author":"Hohnloser","year":"2012","journal-title":"Eur Heart J"},{"key":"10.1016\/j.medcli.2014.07.018_bib0180","doi-asserted-by":"crossref","first-page":"e7097","DOI":"10.1136\/bmj.e7097","article-title":"Primary and secondary prevention with new oral anticoagulant drugs for stroke prevention in atrial fibrillation: indirect comparison analysis","volume":"345","author":"Rasmussen","year":"2012","journal-title":"BMJ"},{"key":"10.1016\/j.medcli.2014.07.018_bib0185","doi-asserted-by":"crossref","first-page":"e77694","DOI":"10.1371\/journal.pone.0077694","article-title":"New oral anticoagulants are not superior to warfarin in secondary prevention of stroke or transient ischemic attacks, but lower the risk of intracranial bleeding: insights from a meta-analysis and indirect treatment comparisons","volume":"8","author":"Sardar","year":"2013","journal-title":"PLoS One"},{"key":"10.1016\/j.medcli.2014.07.018_bib0190","doi-asserted-by":"crossref","first-page":"640723","DOI":"10.1155\/2013\/640723","article-title":"Dabigatran, rivaroxaban, or apixaban versus warfarin in patients with nonvalvular atrial fibrillation: A systematic review and meta-analysis of subgroups","volume":"2013","author":"G\u00f3mez-Outes","year":"2013","journal-title":"Thrombosis"},{"key":"10.1016\/j.medcli.2014.07.018_bib0195","doi-asserted-by":"crossref","first-page":"131","DOI":"10.1161\/CIRCULATIONAHA.110.977546","article-title":"Dabigatran versus warfarin in patients with atrial fibrillation: An analysis of patients undergoing cardioversion","volume":"123","author":"Nagarakanti","year":"2011","journal-title":"Circulation"},{"key":"10.1016\/j.medcli.2014.07.018_bib0200","doi-asserted-by":"crossref","first-page":"1998","DOI":"10.1016\/j.jacc.2013.02.025","article-title":"Outcomes after cardioversion and atrial fibrillation ablation in patients treated with rivaroxaban and warfarin in the ROCKET AF trial","volume":"61","author":"Piccini","year":"2013","journal-title":"J Am Coll Cardiol"},{"key":"10.1016\/j.medcli.2014.07.018_bib0205","doi-asserted-by":"crossref","first-page":"1082","DOI":"10.1016\/j.jacc.2013.09.062","article-title":"Efficacy and safety of apixaban in patients after cardioversion for atrial fibrillation: Insights from the ARISTOTLE Trial (Apixaban for Reduction in Stroke and Other Thromboembolic Events in Atrial Fibrillation)","volume":"63","author":"Flaker","year":"2014","journal-title":"J Am Coll Cardiol"},{"key":"10.1016\/j.medcli.2014.07.018_bib0210","doi-asserted-by":"crossref","first-page":"584","DOI":"10.1160\/TH11-11-0784","article-title":"Net clinical benefit of new oral anticoagulants (dabigatran, rivaroxaban, apixaban) versus no treatment in a \u2018real world\u2019 atrial fibrillation population: A modelling analysis based on a nationwide cohort study","volume":"107","author":"Banerjee","year":"2012","journal-title":"Thromb Haemost"},{"key":"10.1016\/j.medcli.2014.07.018_bib0215","doi-asserted-by":"crossref","first-page":"E40","DOI":"10.1002\/clc.22069","article-title":"Dabigatran compared with warfarin for stroke prevention with atrial fibrillation: Experience in Hong Kong","volume":"35","author":"Ho","year":"2012","journal-title":"Clin Cardiol"},{"key":"10.1016\/j.medcli.2014.07.018_bib0220","doi-asserted-by":"crossref","first-page":"1317","DOI":"10.1185\/03007995.2014.907140","article-title":"Real-world comparative effectiveness and safety of rivaroxaban and warfarin in nonvalvular atrial fibrillation patients","volume":"30","author":"Lalibert\u00e9","year":"2014","journal-title":"Curr Med Res Opin"},{"key":"10.1016\/j.medcli.2014.07.018_bib0225","doi-asserted-by":"crossref","first-page":"2264","DOI":"10.1016\/j.jacc.2013.03.020","article-title":"Efficacy and safety of dabigatran etexilate and warfarin in \u2018real-world\u2019 patients with atrial fibrillation: A prospective nationwide cohort study","volume":"61","author":"Larsen","year":"2013","journal-title":"J Am Coll Cardiol"},{"key":"10.1016\/j.medcli.2014.07.018_bib0230","doi-asserted-by":"crossref","first-page":"e002758","DOI":"10.1136\/bmjopen-2013-002758","article-title":"Dabigatran use in Danish atrial fibrillation patients in 2011: A nationwide study","volume":"3","author":"S\u00f8rensen","year":"2013","journal-title":"BMJ Open"},{"key":"10.1016\/j.medcli.2014.07.018_bib0235","article-title":"Patterns of Adherence to Dabigatran and its Association with Outcomes","author":"Shore","year":"2013","journal-title":"AHA Scientific Sessions"},{"key":"10.1016\/j.medcli.2014.07.018_bib0240","unstructured":"Informe de posicionamiento terap\u00e9utico UT\/V4\/23122013. Criterios y recomendaciones generales para el uso de nuevos anticoagulantes orales (NACO) en la prevenci\u00f3n del ictus y la embolia sist\u00e9mica en pacientes con fibrilaci\u00f3n auricular no valvular. Agencia Espa\u00f1ola de Medicamentos y Productos Sanitarios. Ministerio de Sanidad, Servicios Sociales e Igualdad. Dic 2013."},{"key":"10.1016\/j.medcli.2014.07.018_bib0245","doi-asserted-by":"crossref","first-page":"507","DOI":"10.1007\/s11239-013-0989-6","article-title":"Comparison of cost-effectiveness of anticoagulation with dabigatran, rivaroxaban and apixaban in patients with non-valvular atrial fibrillation across countries","volume":"37","author":"Krejczy","year":"2014","journal-title":"J Thromb Thrombolysis"},{"key":"10.1016\/j.medcli.2014.07.018_bib0250","doi-asserted-by":"crossref","first-page":"1676","DOI":"10.1161\/STROKEAHA.111.000402","article-title":"Cost-effectiveness of apixaban, dabigatran, rivaroxaban, and warfarin for stroke prevention in atrial fibrillation","volume":"44","author":"Harrington","year":"2013","journal-title":"Stroke"},{"key":"10.1016\/j.medcli.2014.07.018_bib0255","doi-asserted-by":"crossref","first-page":"498","DOI":"10.1016\/j.jval.2013.01.009","article-title":"Cost-effectiveness of new oral anticoagulants compared with warfarin in preventing stroke and other cardiovascular events in patients with atrial fibrillation","volume":"16","author":"Coyle","year":"2013","journal-title":"Value Health"},{"key":"10.1016\/j.medcli.2014.07.018_bib0260","doi-asserted-by":"crossref","first-page":"192","DOI":"10.1016\/j.clinthera.2013.12.011","article-title":"Cost-effectiveness of apixaban versus other new oral anticoagulants for stroke prevention in atrial fibrillation","volume":"36","author":"Lip","year":"2014","journal-title":"Clin Ther"},{"key":"10.1016\/j.medcli.2014.07.018_bib0265","doi-asserted-by":"crossref","first-page":"e62183","DOI":"10.1371\/journal.pone.0062183","article-title":"Novel anticoagulants for stroke prevention in atrial fibrillation: A systematic review of cost-effectiveness models","volume":"8","author":"Limone","year":"2013","journal-title":"PLoS One"},{"key":"10.1016\/j.medcli.2014.07.018_bib0270","doi-asserted-by":"crossref","first-page":"46","DOI":"10.1186\/1755-7682-6-46","article-title":"A new era of stroke prevention in atrial fibrillation: Comparing a new generation of oral anticoagulants with warfarin","volume":"6","author":"Stambler","year":"2013","journal-title":"Int Arch Med"}],"container-title":["Medicina Cl\u00ednica"],"original-title":[],"language":"es","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0025775314005697?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0025775314005697?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2018,9,30]],"date-time":"2018-09-30T03:23:08Z","timestamp":1538277788000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0025775314005697"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2015,8]]},"references-count":54,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2015,8]]}},"alternative-id":["S0025775314005697"],"URL":"https:\/\/doi.org\/10.1016\/j.medcli.2014.07.018","relation":{},"ISSN":["0025-7753"],"issn-type":[{"value":"0025-7753","type":"print"}],"subject":[],"published":{"date-parts":[[2015,8]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Avances en el tratamiento anticoagulante de la fibrilaci\u00f3n auricular","name":"articletitle","label":"Article Title"},{"value":"Medicina Cl\u00ednica","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.medcli.2014.07.018","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"Copyright \u00a9 2014 Elsevier Espa\u00f1a, S.L.U. All rights reserved.","name":"copyright","label":"Copyright"}]}}